Compugen Stock (NASDAQ:CGEN), Trade Ideas

Compugen

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Earnings

News

Penny Stocks

Eurozone

Commodities

Global

Intraday Update

Markets

Trading Ideas

BCAN

BDRX

CGEN

IFBD

Intelligent Bio Solutions Inc. - Common Stock

INBS

MOTS

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 200 points on Tuesday.

The Dow traded up 0.53% to 37,505.25 while the NASDAQ rose 0.51% to 14,980.71. The S&amp;P 500 also rose, gaining, 0.45% to 4,762.12.

Crude Oil Rises Over 1%; Biodexa Pharmaceuticals Shares Plunge

Small Cap

Movers

AFRM

BIAF

BKYI

BLUE

BMRA

BNZI

CHWY

CIFR

CKPT

CVAC

ETAO

ICCT

IVVD

LGMK

LIDR

MARA

MIND

NOVA

OPXS

PBLA

QURE

SFWL

TCRT

YOSH

ZJYL

ZVSA

Shares of Compugen Ltd.  (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program.

Compugen shares jumped 204.1% to $2.22 on Tuesday.

Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 150 points on Tuesday.

The Dow traded up 0.46% to 37,476.21 while the NASDAQ rose 0.41% to 14,966.74. The S&amp;P 500 also rose, gaining, 0.38% to 4,758.55.

Dow Jumps 150 Points; FactSet Shares Rise After Q1 Results

Compugen Ltd

Compugen Reports Publication Of Paper In Cancer Immunology Research Demonstrating Therapeutic Potential Of COM503

Truist Securities analyst Asthika Goonewardene maintains Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) with a Buy and raises the price target from $4 to $5.

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Compugen, Raises Price Target to $5

WIIM

Compugen shares are trading lower after the company reported worse-than-expected Q4 EPS results.

Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.23 by 52.17 percent. This is a 375 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $33.46 million which beat the analyst consensus estimate of $20.00 million by 67.30 percent. This is a 346.12 percent increase over sales of $7.50 million the same period last year.

Compugen Q4 EPS $0.11 Misses $0.23 Estimate, Sales $33.46M Beat $20.00M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.
&bull; Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) is estimated to report quarterly earnings at $2.22 per share on revenue of $29.33 billion.
&bull; 2seventy bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>) is expected to report quarterly loss at $0.99 per share on revenue of $14.71 million.
&bull; CLPS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPS#NASDAQ">CLPS</a>) is expected to report earnings for its first quarter.
&bull; Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) is projected to report quarterly loss at $0.50 per share on revenue of $350 thousand.
&bull; Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $183.67 million.
&bull; Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) is projected to report quarterly loss at $1.39 per share on revenue of $2.55 million.
&bull; Consolidated Comms Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSL#NASDAQ">CNSL</a>) is likely to report quarterly loss at $0.36 per share on revenue of $276.94 million.
&bull; CECO Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) is likely to report quarterly earnings at $0.24 per share on revenue of $146.61 million.
&bull; 908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) is expected to report quarterly loss at $0.26 per share on revenue of $14.16 million.
&bull; Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) is projected to report quarterly loss at $0.26 per share on revenue of $19.85 million.
&bull; Broadwind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWEN#NASDAQ">BWEN</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $50.15 million.
&bull; Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) is projected to report quarterly loss at $0.03 per share on revenue of $541.17 million.
&bull; Riskified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $84.02 million.
&bull; Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $9.00 million.
&bull; L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $129.35 million.
&bull; Rand Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAND#NASDAQ">RAND</a>) is expected to report earnings for its fourth quarter.
&bull; Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) is likely to report earnings for its fourth quarter.
&bull; Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) is projected to report quarterly loss at $0.26 per share on revenue of $17.33 million.
&bull; First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $237.53 million.
&bull; Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $20.00 million.
&bull; SmartRent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) is likely to report quarterly loss at $0.01 per share on revenue of $59.49 million.
&bull; Ferguson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) is estimated to report quarterly earnings at $1.85 per share on revenue of $6.77 billion.
&bull; Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $41.78 million.
&bull; Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) is likely to report quarterly loss at $0.10 per share on revenue of $41.65 million.
&bull; V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $1.01 billion.
&bull; Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) is likely to report earnings for its fourth quarter.
&bull; Myers Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $196.19 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is estimated to report quarterly earnings at $0.80 per share on revenue of $197.70 million.
&bull; Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is estimated to report quarterly earnings at $0.88 per share on revenue of $4.39 billion.
&bull; BlackRock Cap Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKCC#NASDAQ">BKCC</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $20.32 million.
&bull; Presto Automation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRST#NASDAQ">PRST</a>) is likely to report earnings for its fourth quarter.
&bull; Kingsway Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFS#NYSE">KFS</a>) is likely to report earnings for its fourth quarter.
&bull; Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) is expected to report quarterly loss at $0.19 per share on revenue of $293.53 million.
&bull; Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) is likely to report earnings for its fourth quarter.
&bull; TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) is likely to report quarterly loss at $0.08 per share on revenue of $1.00 million.
&bull; Entravision Comms (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVC#NYSE">EVC</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $308.47 million.
&bull; Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) is projected to report quarterly loss at $0.87 per share on revenue of $10.58 million.
&bull; Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) is likely to report quarterly loss at $3.66 per share on revenue of $73.50 million.
&bull; Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) is expected to report quarterly loss at $0.62 per share on revenue of $8.01 million.
&bull; Allient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNT#NASDAQ">ALNT</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $132.56 million.
&bull; Bristow Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTOL#NYSE">VTOL</a>) is projected to report quarterly earnings at $0.54 per share on revenue of $329.20 million.
&bull; Greenlight Capital Re (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLRE#NASDAQ">GLRE</a>) is estimated to report earnings for its fourth quarter.
&bull; Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $34.10 million.
&bull; Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) is projected to report quarterly loss at $1.07 per share on revenue of $1.06 million.
&bull; Socket Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCKT#NASDAQ">SCKT</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $4.91 million.
&bull; Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) is expected to report quarterly loss at $0.40 per share on revenue of $1.95 million.
&bull; Park-Ohio Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PKOH#NASDAQ">PKOH</a>) is likely to report quarterly earnings at $0.55 per share on revenue of $386.45 million.
&bull; W&amp;T Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $138.42 million.
&bull; Cadre Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDRE#NYSE">CDRE</a>) is projected to report quarterly earnings at $0.18 per share on revenue of $121.79 million.
&bull; Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $14.50 million.
&bull; Agiliti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGTI#NYSE">AGTI</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $291.41 million.
&bull; Nuvei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEI#NASDAQ">NVEI</a>) is projected to report quarterly earnings at $0.45 per share on revenue of $319.51 million.
&bull; Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) is estimated to report quarterly earnings at $0.84 per share on revenue of $283.00 million.
&bull; Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $152.30 million.
&bull; Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) is likely to report quarterly loss at $0.08 per share on revenue of $11.63 million.
&bull; Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) is expected to report earnings for its fourth quarter.
&bull; MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $74.86 million.
&bull; Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) is likely to report earnings for its fourth quarter.
&bull; Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) is expected to report quarterly loss at $0.02 per share on revenue of $49.27 million.
&bull; American Public Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $150.47 million.
&bull; Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $249.68 million.
&bull; Crexendo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $13.80 million.
&bull; Aeva Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NYSE">AEVA</a>) is likely to report quarterly loss at $0.15 per share on revenue of $1.57 million.
&bull; LSB Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXU#NYSE">LXU</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $127.21 million.
&bull; PlayAGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGS#NYSE">AGS</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $92.57 million.
&bull; Full House Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLL#NASDAQ">FLL</a>) is likely to report quarterly loss at $0.14 per share on revenue of $63.13 million.
&bull; CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is expected to report quarterly earnings at $0.82 per share on revenue of $839.04 million.
&bull; HashiCorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCP#NASDAQ">HCP</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $149.29 million.
&bull; Banco BBVA Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAR#NYSE">BBAR</a>) is estimated to report earnings for its fourth quarter.
&bull; NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) is expected to report quarterly loss at $0.31 per share on revenue of $17.46 million.
&bull; Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) is projected to report earnings for its fourth quarter.
&bull; Ooma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $61.46 million.
&bull; ChargePoint Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) is likely to report quarterly loss at $0.13 per share on revenue of $119.59 million.
&bull; ODDITY Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) is expected to report earnings for its fourth quarter.
&bull; NewtekOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEWT#NASDAQ">NEWT</a>) is projected to report quarterly earnings at $0.58 per share on revenue of $63.35 million.
&bull; Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) is expected to report quarterly earnings at $0.38 per share on revenue of $262.95 million.
&bull; Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) is projected to report earnings for its fourth quarter.
&bull; Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) is likely to report earnings for its fourth quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AEVA

AGTI

ALNT

AOMR

APEI

AQST

AXGN

BASE

BBAR

BKCC

BNGO

BWEN

CDRE

CECO

CERS

CHPT

CLPS

CNSL

CPIX

CRCT

CRWD

CXDO

DAVE

FERG

FSTR

FWRG

GBTG

GLRE

ISPO

MASS

MCRB

MLNK

MRNS

NEWT

NPCE

NUWE

NVEI

NYXH

OFIX

OOMA

PKOH

PRST

PSTV

RAND

RIGL

ROST

RSKD

SCKT

SEAT

SMLR

SMRT

SOPH

STIM

TCON

TSVT

VTOL

WEYS

Earnings Scheduled For March 5, 2024

Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-03-05. Here's what investors need to know before the announcement.
Analysts estimate that Compugen will report an earnings per share (EPS) of $0.22. 
Compugen bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.02, which was followed by a 5.93% drop in the share price the next day.
Here's a look at Compugen's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.09</td>
<td>-0.13</td>
<td>-0.12</td>
<td>-0.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.11</td>
<td>-0.11</td>
<td>-0.11</td>
<td>-0.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>2.0%</td>
<td>-5.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709571707_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Compugen were trading at $2.64 as of March 01. Over the last 52-week period, shares are up 243.79%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/CGEN/earnings">To track all earnings releases for Compugen visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Compugen

Earlier Compugen Announced It Regained Compliance With Nasdaq Minimum Bid Price Requirement

Biotech

General

Compugen To Receive $10M Milestone Payment Following Dosing of First Patient In AstraZeneca's Phase 3 Rilvegostomig Trial In Biliary Tract Cancer

Stifel analyst Stephen Willey maintains Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) with a Buy and raises the price target from $3 to $4.

Stifel Maintains Buy on Compugen, Raises Price Target to $4

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 200 points on Tuesday.
The Dow traded up 0.53% to 37,505.25 while the NASDAQ rose 0.51% to 14,980.71. The S&amp;P 500 also rose, gaining, 0.45% to 4,762.12.
Check This Out: <a href="https://www.benzinga.com/news/23/12/36301521/cisco-systems-electronic-arts-and-2-other-stocks-insiders-are-selling"> Cisco Systems, Electronic Arts And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Materials shares jumped by 1.1% on Tuesday.
In trading on Tuesday, consumer staples shares rose by just 0.1%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Building permits in the U.S. declined by 2.5% to an annual rate of 1.460 million in November, down from market estimates of 1.470 million.
U.S. housing starts surged 14.8% month-over-month to an annualized 1.56 million in November, compared to market estimates of 1.36 million.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Compugen Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgen#NASDAQ">CGEN</a>) shares shot up 161% to $1.9065 after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program.
Shares of Intelligent Bio Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inbs#NASDAQ">INBS</a>) got a boost, surging 27% to $0.3550. Intelligent Bio Solutions received National Association of Testing Authorities accreditation for its Intelligent Fingerprinting Drug Screening Solution.
Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) shares were also up, gaining 17% to $1.5810 after the company inked a new business cooperation in software development of information technology system.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Motus GI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mots#NASDAQ">MOTS</a>) shares dropped 34% to $1.4191 after the company priced its $5 million public offering.
Shares of BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) were down 49% to $0.3530 after the company reported pricing of $1.5 million registered direct offering.
Biodexa Pharmaceuticals Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bdrx#NASDAQ">BDRX</a>) was down, falling 17% to $2.52 after the company disclosed the pricing of $5.2 million underwritten public offering.
Also Check This Out:<a href="https://www.benzinga.com/news/earnings/23/12/36296621/how-to-earn-500-a-month-from-general-mills-stock-ahead-of-quarterly-earnings-report"> How To Earn $500 A Month From General Mills Stock Ahead of Quarterly Earnings Report</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 1.33e% to $73.43 while gold traded up 0.7% at $2,055.00.
Silver traded up 1% to $24.355 on Tuesday while copper rose 1.3% to $3.90.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares closed higher today. The eurozone&rsquo;s STOXX 600 gained 0.36%, London&rsquo;s FTSE 100 gained 0.31% while Spain&rsquo;s IBEX 35 Index rose 0.52% The German DAX rose 0.56% French CAC 40 rose 0.08%, while Italy&rsquo;s FTSE MIB Index rose 0.41%.
Annual inflation rate in the Eurozone eased to 2.4% in November from 2.9% in the previous month.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly higher on Tuesday, with Japan&rsquo;s Nikkei 225 gaining 1.41%, Hong Kong&rsquo;s Hang Seng Index declining 0.75% and China&rsquo;s Shanghai Composite Index gaining 0.05%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, rose 0.17%.
Hong Kong&rsquo;s unemployment rate came in unchanged at 2.9% for the three months ending Nov. 2023. The Bank of Japan held its key short-term interest rate at -0.1% during its latest meeting.
&nbsp;
<h3>Economics</h3>
&nbsp;
Building permits in the U.S. declined by 2.5% to an annual rate of 1.460 million in November, down from market estimates of 1.470 million.
U.S. housing starts surged 14.8% month-over-month to an annualized 1.56 million in November, compared to market estimates of 1.36 million.
Now Read This: <a href="https://www.benzinga.com/news/23/12/36301788/top-5-financial-stocks-that-may-keep-you-up-at-night-in-december"> Top 5 Financial Stocks That May Keep You Up At Night In December</a>
&nbsp;

Shares of Compugen Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgen#NASDAQ">CGEN</a>) shares rose sharply during Tuesday&rsquo;s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program.
Compugen shares jumped 204.1% to $2.22 on Tuesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Intelligent Bio Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inbs#NASDAQ">INBS</a>) gained 73% to $0.4853. Intelligent Bio Solutions received National Association of Testing Authorities accreditation for its Intelligent Fingerprinting Drug Screening Solution.</li>
<li>Panbela Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pbla#NASDAQ">PBLA</a>) shares surged 64% to $1.6601. Panbela Therapeutics shares jumped 120% on Monday after US WorldMeds received FDA approval of eflornithine.</li>
<li>Jin Medical International Ltd.(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zjyl#NASDAQ">ZJYL</a>) climbed 49.2% to $151.96 after jumping around 264% on Monday.</li>
<li>ProSomnus, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/osa#NASDAQ">OSA</a>) gained 27.6% to $0.8017. ProSomnus announced data published by Cureus Journal of Medical Science showed successful treatment of obstructive sleep apnea with prosomnus precision oral appliance devices.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) shares gained 27.4% to $1.7266 after the company inked a new business cooperation in software development of information technology system.</li>
<li>MIND Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mind#NASDAQ">MIND</a>) rose 23.1% to $5.86.</li>
<li>Yoshiharu Global Co. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yosh#NASDAQ">YOSH</a>) rose 21.1% to $6.20.</li>
<li>Optex Systems Holdings, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opxs#NASDAQ">OPXS</a>) gained 18.2% to $4.86.</li>
<li>Sunnova Energy International Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nova#NASDAQ">NOVA</a>) jumped 16.3% to $15.32. Piper Sandler upgraded Sunnova Energy Intl from Neutral to Overweight and raised the price target from $13 to $26.</li>
<li>Cipher Mining Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cifr#NASDAQ">CIFR</a>) rose 16% to $3.6450.</li>
<li>LogicMark, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgmk#NASDAQ">LGMK</a>) gained 15.7% to $1.0650.</li>
<li>Checkpoint Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ckpt#NASDAQ">CKPT</a>) climbed 13.8% to $2.0825. HC Wainwright &amp; Co. reiterated Checkpoint Therapeutics with a Buy and maintained a $34 price target.</li>
<li>Affirm Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/afrm#NASDAQ">AFRM</a>) gained 13.6% to $49.64 after the company announced it has expanded its services to self-checkout at Walmart stores.</li>
<li>PureCycle Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pct#NASDAQ">PCT</a>) gained 13.2% to $3.17. Roth MKM downgraded PureCycle Technologies from Buy to Neutral and lowered the price target from $6 to $3.</li>
<li>bioAffinity Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biaf#NASDAQ">BIAF</a>) rose 12.2% to $1.57.</li>
<li>Sunrun Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/run#NASDAQ">RUN</a>) gained 9.4% to $19.72 after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $15 to $31.</li>
<li>Chewy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chwy#NYSE">CHWY</a>) rose 7.1% to $23.22. Jefferies initiated coverage on Chewy with a Buy rating and announced a price target of $27.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mara#NASDAQ">MARA</a>) gained 6% to $21.09. Marathon Digital entered into a definitive agreement Tuesday to acquire two <a href="https://www.benzinga.com/money/bitcoin-mining-software/">Bitcoin mining</a> sites for $178.6 million.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) fell 49.3% to $0.3501 after the company reported pricing of $1.5 million registered direct offering.</li>
<li>Motus GI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mots#NASDAQ">MOTS</a>) shares fell 45.6% to $1.17 after the company priced its $5 million public offering.</li>
<li>CureVac N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvac#NASDAQ">CVAC</a>) declined 35.7% to $3.7384. CureVac announced decision of German Federal Patent Court in broad patent litigation with BioNTech SE.</li>
<li>ETAO International Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etao#NASDAQ">ETAO</a>) fell 34.7% to $0.3001. ETAO International received a staff determination letter, on Dec. 13, 2023, from the Listing Qualifications Department of The Nasdaq Stock Market LLC.</li>
<li>Shengfeng Development Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sfwl#NASDAQ">SFWL</a>) declined 32.4% to $3.24.</li>
<li>Banzai International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bnzi#NASDAQ">BNZI</a>) fell 26.5% to $4.5006.</li>
<li>Biodexa Pharmaceuticals Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bdrx#NASDAQ">BDRX</a>) declined 20.2% to $2.4150 after the company disclosed the pricing of a public offering.</li>
<li>AEye, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lidr#NASDAQ">LIDR</a>) fell 18.8% to $0.0820. Representatives of Continental informed AEye that Continental intends to discontinue the parties&#39; joint lidar development program, including any further development of the HRL131 lidar product line.</li>
<li>Invivyd, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ivvd#NASDAQ">IVVD</a>) fell 16.4% to $3.00. Morgan Stanley upgraded Invivyd from Underweight to Equal-Weight and raised the price target from $1 to $4.</li>
<li>Biomerica, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmra#NASDAQ">BMRA</a>) shares fell 16.3% to $1.3798. Biomerica shares gained around 67% on Monday after the company received FDA 510(k) clearance for its Hp Detect ELISA test product.</li>
<li>BIO-key International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bkyi#NASDAQ">BKYI</a>) declined 16.3% to $0.1461. Following stockholder approval, BIO-Key announced a 1-for-18 reverse stock split to regain compliance with Nasdaq minimum bid price requirement.</li>
<li>bluebird bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blue#NASDAQ">BLUE</a>) shares fell 14.2% to $2.6180 after the company announced a proposed public offering of $150 million of common stock.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zvsa#NASDAQ">ZVSA</a>) fell 14% to $0.92 after surging 38% on Monday.</li>
<li>Diversified Energy Co PLC (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dec#NYSE">DEC</a>) declined 12% to $15.77.</li>
<li>Alaunos Therapeutics, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcrt#NASDAQ">TCRT</a>) fell 10.6% to $0.0513 after jumping 26% on Monday.</li>
<li>uniQure N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qure#NASDAQ">QURE</a>) fell 9.8% to $7.20 after announcing updated interim data on Phase I/II clinical trials of AMT-130 gene therapy for the treatment of Huntington&#39;s disease.</li>
<li>iCoreConnect Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icct#NASDAQ">ICCT</a>) fell 8.3% to $2.1193 after jumping over 35% on Monday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/12/36296621/how-to-earn-500-a-month-from-general-mills-stock-ahead-of-quarterly-earnings-report"> How To Earn $500 A Month From General Mills Stock Ahead of Quarterly Earnings Report</a>

Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 150 points on Tuesday.
The Dow traded up 0.46% to 37,476.21 while the NASDAQ rose 0.41% to 14,966.74. The S&amp;P 500 also rose, gaining, 0.38% to 4,758.55.
Check This Out: <a href="https://www.benzinga.com/news/23/12/36301521/cisco-systems-electronic-arts-and-2-other-stocks-insiders-are-selling"> Cisco Systems, Electronic Arts And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Materials shares rose by 1% on Tuesday.
In trading on Tuesday, information technology shares fell by 0.1%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Shares of FactSet Research Systems Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fds#NYSE">FDS</a>) gained on Tuesday after the company reported earnings results for its first quarter.
FactSet Research reported quarterly sales growth of 7.4% Y/Y to $542.2 million, marginally beating the consensus of $540.36 million. Adjusted EPS of $4.12 beat the consensus of $4.11.
FactSet lowered FY24 revenue outlook to $2.20 billion-$2.21 billion (from $2.21 billion-$2.23 billion) vs. $2.22 billion estimate and adj. EPS to $15.60-$16.00 (from $15.65-$16.15) vs. consensus of $16.08.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Compugen Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgen#NASDAQ">CGEN</a>) shares shot up 159% to $1.8901 after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program.
Shares of Intelligent Bio Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inbs#NASDAQ">INBS</a>) got a boost, surging 57% to $0.4391. Intelligent Bio Solutions received National Association of Testing Authorities accreditation for its Intelligent Fingerprinting Drug Screening Solution.
Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) shares were also up, gaining 23% to $1.66 after the company inked a new business cooperation in software development of information technology system.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Motus GI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mots#NASDAQ">MOTS</a>) shares dropped 45% to $1.18 after the company priced its $5 million public offering.
Shares of BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) were down 44% to $0.3849 after the company reported pricing of $1.5 million registered direct offering.
Biodexa Pharmaceuticals Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bdrx#NASDAQ">BDRX</a>) was down, falling 20% to $2.43 after the company disclosed the pricing of $5.2 million underwritten public offering.
Also Check This Out:<a href="https://www.benzinga.com/news/earnings/23/12/36296621/how-to-earn-500-a-month-from-general-mills-stock-ahead-of-quarterly-earnings-report"> How To Earn $500 A Month From General Mills Stock Ahead of Quarterly Earnings Report</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 0.8% to $73.08 while gold traded up 0.7% at $2,055.30.
Silver traded up 1.2% to $24.40 on Tuesday while copper rose 1.9% to $3.9245.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly higher today. The eurozone&rsquo;s STOXX 600 gained 0.28%, London&rsquo;s FTSE 100 gained 0.16% while Spain&rsquo;s IBEX 35 Index rose 0.29% The German DAX rose 0.44% French CAC 40 rose 0.02%, while Italy&rsquo;s FTSE MIB Index rose 0.23%.
Annual inflation rate in the Eurozone eased to 2.4% in November from 2.9% in the previous month.
&nbsp;
Asia Pacific Markets
Asian markets closed mostly higher on Tuesday, with Japan&rsquo;s Nikkei 225 gaining 1.41%, Hong Kong&rsquo;s Hang Seng Index declining 0.75% and China&rsquo;s Shanghai Composite Index gaining 0.05%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, rose 0.17%.
Hong Kong&rsquo;s unemployment rate came in unchanged at 2.9% for the three months ending Nov. 2023. The Bank of Japan held its key short-term interest rate at -0.1% during its latest meeting.
&nbsp;
<h3>Economics</h3>
&nbsp;
Building permits in the U.S. declined by 2.5% to an annual rate of 1.460 million in November, down from market estimates of 1.470 million.
U.S. housing starts surged 14.8% month-over-month to an annualized 1.56 million in November, compared to market estimates of 1.36 million.
Now Read This: <a href="https://www.benzinga.com/news/23/12/36301788/top-5-financial-stocks-that-may-keep-you-up-at-night-in-december"> Top 5 Financial Stocks That May Keep You Up At Night In December</a>

Gilead Sciences Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gild#NASDAQ">GILD</a>) announced an agreement with&nbsp;Compugen Ltd&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgen#NASDAQ">CGEN</a>) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/12/b36300036/gilead-and-compugen-announce-exclusive-license-agreement-for-novel-pre-clinical-immunotherapy-prog" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">COM503 drug candidate</a>.
COM503 is a potential first-in-class, high-affinity antibody that blocks the interaction between IL-18 binding protein and IL-18, releasing natural IL-18 in the tumor microenvironment and inhibiting cancer growth.
Under the terms of the agreement, Compugen will be responsible for the ongoing pre-clinical development and the future Phase 1 study of COM503. After that, Gilead will have the sole right to develop and commercialize COM503.
Gilead will make Compugen an upfront payment of $60 million and $30 million in a near-term milestone payment subject to IND clearance of COM503 expected in 2024.&nbsp;
Compugen will also be eligible to receive up to an additional $758 million in future development, regulatory, and commercial milestone payments, with a total deal value of $848 million.&nbsp;
Compugen will also be eligible to receive single-digit to low double-digit tiered royalties on worldwide net sales.
This transaction with Compugen is expected to reduce Gilead&#39;s GAAP and non-GAAP 2023 EPS by approximately $0.03-$0.05.
Concurrently, Compugen also said it will be eligible to receive a milestone payment of $10 million from&nbsp;AstraZeneca Plc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/azn#NASDAQ">AZN</a>) when the first patient is dosed in AstraZeneca&#39;s ARTEMIDE-Bil01 trial with rilvegostomig derived from Compugen&#39;s clinical-stage&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/12/n36300322/compugen-will-be-eligible-to-receive-10-million-milestone-payment-upon-dosing-of-first-patient-in-" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">anti-TIGIT antibody, COM902</a>.&nbsp;
The ARTEMIDE-Bil01 trial is expected to recruit about 750 subjects with biliary tract cancer.
Price Action:&nbsp;CGEN shares are up 152.10% at $1.84 on the last check Tuesday.

Large Cap

Health Care

Contracts

GILD

Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today?

Compugen Shares Resume Trade

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.17% to 37,369.84 while the NASDAQ rose 0.25% to 14,941.77. The S&amp;P 500 also rose, gaining, 0.17% to 4,748.81.
Check This Out: <a href="https://www.benzinga.com/news/23/12/36301521/cisco-systems-electronic-arts-and-2-other-stocks-insiders-are-selling"> Cisco Systems, Electronic Arts And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Materials shares rose by 0.7% on Tuesday.
In trading on Tuesday, financial shares fell by 0.1%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Accenture Plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/acn#NYSE">ACN</a>) posted upbeat earnings for its first quarter, but issued weak sales outlook.
Accenture reported quarterly sales of $16.22 billion compared with the consensus of $16.20 billion, an increase of 3% Y/Y in U.S. dollars and 1% in local currency. Adjusted earnings came in at $3.27 per share, versus expectations of $3.14 per share.
Accenture expects second-quarter revenues of $15.40 billion to $16.00 billion (versus consensus of $16.25 billion), or negative 2% to 2% in local currency, reflecting the company&rsquo;s assumption of a negative 0.5% foreign-exchange impact compared with the second quarter of fiscal 2023.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Compugen Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgen#NASDAQ">CGEN</a>) shares shot up 218% to $2.32 after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program.
Shares of Panbela Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pbla#NASDAQ">PBLA</a>) got a boost, surging 78% to $1.79. Panbela Therapeutics shares jumped 120% on Monday after US WorldMeds received FDA approval of eflornithine.
Jin Medical International Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zjyl#NASDAQ">ZJYL</a>) shares were also up, gaining 65% to $168.00 after jumping around 264% on Monday.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Motus GI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mots#NASDAQ">MOTS</a>) shares dropped 43% to $1.23 after the company priced its $5 million public offering.
Shares of BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) were down 44% to $0.3877 after the company reported pricing of $1.5 million registered direct offering.
ETAO International Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etao#NASDAQ">ETAO</a>) was down, falling 39% to $0.2810. ETAO International received a staff determination letter, on Dec. 13, 2023, from the Listing Qualifications Department of The Nasdaq Stock Market LLC.
Also Check This Out:<a href="https://www.benzinga.com/news/earnings/23/12/36296621/how-to-earn-500-a-month-from-general-mills-stock-ahead-of-quarterly-earnings-report"> How To Earn $500 A Month From General Mills Stock Ahead of Quarterly Earnings Report</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 0.6% to $72.90 while gold traded up 0.3% at $2,045.50.
Silver traded up 0.6% to $24.25 on Tuesday while copper rose 1.5% to $3.9110.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly higher today. The eurozone&rsquo;s STOXX 600 gained 0.2%, London&rsquo;s FTSE 100 gained 0.1% while Spain&rsquo;s IBEX 35 Index rose 0.4% The German DAX rose 0.4% French CAC 40 fell 0.1%, while Italy&rsquo;s FTSE MIB Index rose 0.2%.
Annual inflation rate in the Eurozone eased to 2.4% in November from 2.9% in the previous month.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly higher on Tuesday, with Japan&rsquo;s Nikkei 225 gaining 1.41%, Hong Kong&rsquo;s Hang Seng Index declining 0.75% and China&rsquo;s Shanghai Composite Index gaining 0.05%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, rose 0.17%.
Hong Kong&rsquo;s unemployment rate came in unchanged at 2.9% for the three months ending Nov. 2023. The Bank of Japan held its key short-term interest rate at -0.1% during its latest meeting.
&nbsp;
<h3>Economics</h3>
&nbsp;
Building permits in the U.S. declined by 2.5% to an annual rate of 1.460 million in November, down from market estimates of 1.470 million.
U.S. housing starts surged 14.8% month-over-month to an annualized 1.56 million in November, compared to market estimates of 1.36 million.
Now Read This: <a href="https://www.benzinga.com/news/23/12/36301788/top-5-financial-stocks-that-may-keep-you-up-at-night-in-december"> Top 5 Financial Stocks That May Keep You Up At Night In December</a>

US Stocks Higher; Accenture Issues Weak Sales Outlook

Compugen Shares Halted On Circuit Breaker To The Upside, Stock Now Up 217.8%

Compugen shares are trading higher after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program.

CGEN: 240% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/36300322">Compugen Says It Will Be Eligible To Receive $10M Milestone Payment Upon Dosing Of First Patient In AstraZeneca Phase 3 Rilvegostomig Trial In Biliary Tract Cancer</a>
IFBD: 152% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/36293324">Infobird Inks New Business Cooperation In Software Development Of Information Technology System</a>
ALDX: 42% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/36300292">Aldeyra Therapeutics&#39; Phase 2 Trial Of ADX-629 For Atopic Dermatitis Shows Statistically Significant And Clinically Relevant Improvement In Investigator-assessed And Patient-reported Outcomes Across Different Physiological And Psychosocial Assessments</a>

ALDX

Market-Moving News for December 19th

Compugen Says It Will Be Eligible To Receive $10M Milestone Payment Upon Dosing Of First Patient In AstraZeneca Phase 3 Rilvegostomig Trial In Biliary Tract Cancer

Beginning in the&nbsp;first quarter&nbsp;of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission (SEC), Gilead no longer excludes acquired IPR&amp;D expenses from its non-GAAP financial measures.

Guidance

Gilead Sciences Expects License Transaction With Compugen To Reduce Its GAAP And Non-GAAP 2023 EPS By Approximately $0.03 - $0.05

Regenxbio, Quoin Pharmaceuticals, Renalytix among healthcare movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Compugen (NASDAQ:<a href="https://investorplace.com/stock-quotes/cgen-stock-quote/">CGEN</a>) just reported results for the fourth quarter of 2023.<ul><li>Compugen reported earnings per share of 11 cents. This was below the analyst estimate for EPS of 23 cents.</li><li>The company reported revenue of $33.46 million.</li><li>This was 67.30% better than the analyst estimate for revenue of $20.00 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/cgen-stock-earnings-compugen-for-q4-of-2023/">CGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023

Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript

The 87 rating InvestorsObserver gives to Compugen Ltd (CGEN)  stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 98 percent of stocks in the Biotechnology industry, CGENâ€&#x2122;s 87 overall rating means the stock scores better than 87 percent of all stocks. CGEN has an Overall Score of 87

Does Compugen Ltd (CGEN) Have What it Takes to be in Your Portfolio Wednesday?

Daina Graybosch, an analyst from Leerink Partners, maintained the Buy rating on Compugen (CGEN – Research Report). The associated price target is $...

Buy Rating Justified by Compugen's Positive Clinical Outlook and Financial Stability

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cigna (CI – Research Report), Compugen (CGEN – Res...

Analysts Offer Insights on Healthcare Companies: Cigna (CI), Compugen (CGEN) and OrthoPediatrics (KIDS)

A rating of 99 puts Compugen Ltd (CGEN) near the top of the Healthcare sector according to InvestorsObserver.Compugen Ltd's score of 99 means that it ranks higher than 99% of stocks in the sector. In addition, its overall score of 92 ranks it higher than 92% of all stocks. CGEN has an Overall Score of 92. Find out what thi

Should You Add Compugen Ltd (CGEN) Stock to Your Portfolio Friday?

Compugen Ltd (CGEN) is higher by Wednesday morning, with the stock gaining 1.07% in pre-market trading to 2.83. CGEN's short-term technical score of 77 indicates that the stock has traded more bullishly over the last month than 77% of stocks on the market. In the Biotechnology industry, which ranks 99 out of 146 industries

Should You Hold Compugen Ltd (CGEN) Stock Wednesday Morning?

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Compugen (CGEN – Research Report). The company's ...

Truist Financial Reaffirms Their Buy Rating on Compugen (CGEN)

The biotech industry's growth prospects look promising due to advanced technologies like AI, the growing popularity of tailored treatments, a rise in chronic diseases, and higher R&D spending. Let's analyze the investment prospects of biotech stocks Innoviva (INVA), Organogenesis Holdings (ORGO), and Compugen (CGEN). Read more... The biotech industry is set for solid growth thanks to continuous innovations and the increasing need for advanced healthcare solutions, innovative vaccines, and therapies. Moreover, investments in research and development (R&amp;D), an aging population, rising demand for personalized medicines, and government initiatives bolster the sector's outlook.
Amid this favorable backdrop, investors could consider buying fundamentally strong biotech stocks: Innoviva, Inc. (<a href="https://stocknews.com/stock/INVA/">INVA</a>), Organogenesis Holdings Inc. (<a href="https://stocknews.com/stock/ORGO/">ORGO</a>), and Compugen Ltd. (<a href="https://stocknews.com/stock/CGEN/">CGEN</a>).
The biotech industry is booming worldwide thanks to significant advancements in drug development, such as targeted therapies and the application of genetic engineering. Increased investments in R&amp;D and a rise in clinical trials will likely boost the industry's prospects. The global biotechnology market is projected to reach $3.88 trillion by 2030, with a <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">CAGR of 14%</a>.
Meanwhile, the advances in AI and machine learning are helping bring innovation to the biotech industry. These technologies help with drug development and streamline manufacturing processes, contributing to the industry's growth. The global AI for Pharma and Biotech market is expected to reach $4.20 billion by 2027, growing at a <a href="https://www.linkedin.com/pulse/ai-pharma-biotech-market-size-2024-growth-u229e/">30.5% CAGR</a>.
Considering these conducive trends, let's analyze the fundamental aspects of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> picks, beginning with the third choice.
Stock #3: Innoviva, Inc. (<a href="https://stocknews.com/stock/INVA/">INVA</a>)
INVA engages in developing and commercializing pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA.
In terms of the trailing-12-month gross profit margin, INVA's 84.09% is 48% higher than the 56.84% industry average. Likewise, its 45.43% trailing-12-month <a href="https://www.investopedia.com/terms/e/ebit.asp">EBIT</a> margin is significantly higher than the 0.80% industry average. Additionally, its 38.85% trailing-12-month levered FCF margin is substantially higher than the 0.65% industry average.
INVA's total revenue for the fourth quarter that ended December 31, 2023, rose 30.4% to $85.84 million. The company's net product sales rose 34.9% over the prior-year quarter to $19.68 million.
In addition, its net income attributable to INVA's stockholders and net income per share came in at $61.53 million and $0.76, respectively, compared to a net loss and net loss per share of $68.31 million and $0.98, respectively, in the year-ago quarter.
Analysts expect INVA's EPS for the quarter ending June 30, 2024, to increase considerably year-over-year to $0.22. Its revenue for the quarter ending September 30, 2024, is expected to grow 8.7% year-over-year to $73.14 million. Over the past year, INVA's stock has gained 25% to close the last trading session at $14.63.
INVA's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect solid prospects. It has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It is ranked #29 out of 360 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. It has an A grade for Value and a B for Quality. <a href="https://stocknews.com/stock/INVA/">Click here</a> to see INVA's Growth, Momentum, Stability, and Sentiment ratings.
Stock #2: Organogenesis Holdings Inc. (<a href="https://stocknews.com/stock/ORGO/">ORGO</a>)
ORGO is a regenerative medicine company that develops, manufactures, and commercializes solutions for the advanced wound care, surgical, and sports medicine markets in the United States.
In terms of the trailing-12-month EBITDA margin, ORGO's 7.32% is 41.2% higher than the 5.18% industry average. Likewise, its 75.42% trailing-12-month gross profit margin is 32.7% higher than the 56.84% industry average. Also, its 0.95x trailing-12-month asset turnover ratio is 140.3% higher than the 0.40x industry average.
For the fiscal year that ended December 31, 2023, ORGO's net revenue came in at $433.14 million. Its gross profit was $326.66 million. The company's adjusted net income stood at $12.68 million, while its net income per share came in at $0.04. Additionally, as of December 31, 2023, its total assets amounted to $460.03 million, compared to $449.36 million as of December 31, 2022.
Analysts expect ORGO's revenue for the quarter ending September 30, 2024, to increase 6.8% year-over-year to $115.90 million. Over the past year, the stock has gained 39.8% to close the last trading session at $2.88.
ORGO's POWR Ratings reflect solid prospects. It has an overall rating of B, which translates to a Buy in our proprietary rating system.
It is ranked #27 out of 360 stocks in the same industry. It has an A grade for Value. <a href="https://stocknews.com/stock/ORGO/">Click here</a> to see ORGO's Growth, Momentum, Stability, Sentiment, and Quality ratings.
Stock #1: Compugen Ltd. (<a href="https://stocknews.com/stock/CGEN/">CGEN</a>)
CGEN is a clinical-stage therapeutic discovery and development company that researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe.
On January 8, 2024, CGEN announced that it is entitled to receive a $10 million milestone payment from AstraZeneca after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig, a PD-1/TIGIT bispecific antibody derived from CGEN's anti-TIGIT antibody.
In terms of the trailing-12-month gross profit margin, CGEN's 94.01% is 65.4% higher than the 56.84% industry average.
For the fiscal fourth quarter ended December 31, 2023, CGEN's revenue increased 346.1% year-over-year to $33.46 million. Its gross profit came in at $31.46 million, up 382.1% over the prior-year quarter.
Additionally, the company's net income and net income per share stood at $9.71 million and $0.11, respectively, compared to the previous year's net loss and net loss per share of $3.09 million and $0.04.
Street expects CGEN's revenue for the fiscal year ending December 31, 2024, to increase 13.3% year-over-year to $37.90 million. It surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, the stock has declined 261.3% to close the last trading session at $2.13.
It's no surprise that CGEN has an overall rating of B, which translates to a Buy in our proprietary rating system.
It has a B grade for Value and Sentiment. Within the Biotech industry, it is ranked #26. Beyond what we stated above, we also have given CGEN grades for Growth, Momentum, Stability, and Quality. Get all the CGEN ratings <a href="https://stocknews.com/stock/CGEN/">here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
INVA shares were trading at $14.54 per share on Monday morning, down $0.09 (-0.62%). Year-to-date, INVA has declined -9.35%, versus a 8.07% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/inva-orgo-cgen-3-biotech-stocks-with-potential-gains-watch-or-buy/>3 Biotech Stocks with Potential Gains - Watch or Buy?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks with Potential Gains - Watch or Buy?

APGE

EKSO

INVA

KIDS

LIPO

OCEA

ORGO

QNRX

RGNX

RNLX

SBFM

Opinion

Press Releases

Thinking about buying stock in Conservative Broadcast Media & Journalism, Chevron, Compugen, Digital World Acquisition, or Rumble?

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024

Compugen to Present at the Leerink Partners Global Biopharma Conference 2024

Thinking about buying stock in Volcon, Abeona Therapeutics, Agenus, Viking Therapeutics, or Compugen?

Compugen Reports Fourth Quarter and Full Year 2023 Results

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

Compugen to Participate in Two Upcoming Investor Conferences

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503